Natalie C. Fisher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Natalie C. Fisher has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Philip David Dunne
Queens University Belfast, Patrick G Johnston Centre for Cancer Research, Belfast, UK
35 shared publications - Raheleh Amirkhah
Queen's University Belfast
31 shared publications - Baharak Ahmaderaghi
School of Electronics, Electrical Engineering and Computer Science, Queen’s University Belfast, Belfast, UK
24 shared publications - Ryan M. Byrne
The Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK
24 shared publications Shania M. Corry
24 shared publications- Sudhir B. Malla
Queen's University Belfast
24 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Average C-reactive protein at each timepoint, in each treatment group
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Average C-reactive protein at each timepoint, in each treatment group
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Concentrations of cytokines in peripheral blood
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Concentrations of cytokines in peripheral blood
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Individual patient microenvironment cell population counter scores
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Individual patient microenvironment cell population counter scores
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Analytes for Bioteche 25-plex Immunopathology Multiplex Cytokine Assay
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Analytes for Bioteche 25-plex Immunopathology Multiplex Cytokine Assay
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Drug names and dosing schedules
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Drug names and dosing schedules
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Waterfall plots representing change in lymphocyte concentrations.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Waterfall plots representing change in lymphocyte concentrations.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Study representativeness table
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Study representativeness table
- 9 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1145-1156
Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Purpose: Two dominant neoadjuvant radiotherapy (RT) regimens are in common use for locally advanced rectal cancer (LARC): long-course RT (LCRT; 25 × 1.8 Gy) with concomitant chemotherapy and short-course RT (SCRT; 5 × 5 Gy), typically followed by systemic chemotherapy. This study uses serial sampling to investigate the evolution of systemic and local immune responses to different RT regimens in LARC. Experimental Design: We conducted a serial sampling study involving patients receiving RT for LARC, in which longitudinal blood and tumor biospecimens were collected at baseline and at 2, 6, and 12 weeks after treatment initiation. Leukocyte concentrations via full blood count and a multiplex cytokine ELISA of plasma samples measured systemic changes. Multiplex immunofluorescence (CD8 and FOXP3) and RNA sequencing of tumor biopsies were used to assess local changes. Results: Circulating lymphocyte concentrations tended to increase in SCRT patients and decrease in LCRT patients between week 2 and week 6 and were significantly lower in LCRT patients compared with SCRT patients at week 6 (P < 0.0001) and week 12 (P = 0.019). Additionally, we report higher densities of CD8+ and FOXP3+ tumoral lymphocytes from SCRT patients compared with LCRT patients at week 2 (CD8 P = 0.053; FOXP3 P = 0.023) and week 6 (CD8 P = 0.035; FOXP3 P = 0.0016). Conclusions: SCRT is less lymphodepleting and induces more frequent increases in intratumoral T-cell infiltration compared with LCRT. These results are relevant to the field of radiation–immune-oncology combination studies in LARC. Furthermore, these findings may underpin early trial results, in which higher rates of response to RT–immune checkpoint inhibitor combinations have been reported with SCRT-based regimens.
- 9 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1145-1156
Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Purpose: Two dominant neoadjuvant radiotherapy (RT) regimens are in common use for locally advanced rectal cancer (LARC): long-course RT (LCRT; 25 × 1.8 Gy) with concomitant chemotherapy and short-course RT (SCRT; 5 × 5 Gy), typically followed by systemic chemotherapy. This study uses serial sampling to investigate the evolution of systemic and local immune responses to different RT regimens in LARC. Experimental Design: We conducted a serial sampling study involving patients receiving RT for LARC, in which longitudinal blood and tumor biospecimens were collected at baseline and at 2, 6, and 12 weeks after treatment initiation. Leukocyte concentrations via full blood count and a multiplex cytokine ELISA of plasma samples measured systemic changes. Multiplex immunofluorescence (CD8 and FOXP3) and RNA sequencing of tumor biopsies were used to assess local changes. Results: Circulating lymphocyte concentrations tended to increase in SCRT patients and decrease in LCRT patients between week 2 and week 6 and were significantly lower in LCRT patients compared with SCRT patients at week 6 (P < 0.0001) and week 12 (P = 0.019). Additionally, we report higher densities of CD8+ and FOXP3+ tumoral lymphocytes from SCRT patients compared with LCRT patients at week 2 (CD8 P = 0.053; FOXP3 P = 0.023) and week 6 (CD8 P = 0.035; FOXP3 P = 0.0016). Conclusions: SCRT is less lymphodepleting and induces more frequent increases in intratumoral T-cell infiltration compared with LCRT. These results are relevant to the field of radiation–immune-oncology combination studies in LARC. Furthermore, these findings may underpin early trial results, in which higher rates of response to RT–immune checkpoint inhibitor combinations have been reported with SCRT-based regimens.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
The ConfoundR resource enables stromal influence estimation in cancer tissue. A, Schematic overview of the cohorts and analyses available within the ConfoundR app, accessible via https://confoundr.qub.ac.uk/. B, Expression Boxplots analysis module of ConfoundR enabling the expression of a single gene to be compared between stroma and epithelium samples in each of the ConfoundR datasets. C, Expression Heatmap analysis module of ConfoundR enabling the expression of multiple genes to be visually compared between stroma and epithelium samples in each of the ConfoundR datasets. D, GSEA analysis module of ConfoundR allowing GSEA of existing gene sets from established gene set collections or custom user defined gene sets to be performed comparing stroma with epithelium in each of the ConfoundR datasets.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
The ConfoundR resource enables stromal influence estimation in cancer tissue. A, Schematic overview of the cohorts and analyses available within the ConfoundR app, accessible via https://confoundr.qub.ac.uk/. B, Expression Boxplots analysis module of ConfoundR enabling the expression of a single gene to be compared between stroma and epithelium samples in each of the ConfoundR datasets. C, Expression Heatmap analysis module of ConfoundR enabling the expression of multiple genes to be visually compared between stroma and epithelium samples in each of the ConfoundR datasets. D, GSEA analysis module of ConfoundR allowing GSEA of existing gene sets from established gene set collections or custom user defined gene sets to be performed comparing stroma with epithelium in each of the ConfoundR datasets.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
Single-cell and multi-regional biopsy analyses. A, Schematic of scRNA-seq cohort derived from n = 6 CRC primary tumors. Boxplots showing ssGSEA scores for the Hallmark Epithelial Mesenchymal Transition gene set across the various cell types (B) and specifically between epithelial and stromal cells (C; from all six colorectal cancer tumors) in the scRNA-seq dataset (P < 2.2 × 10–16; Wilcoxon test). D, Comparison of ssGSEA scores for the Hallmark Epithelial Mesenchymal Transition gene set between epithelial and stromal cells in each primary CRC (n = 6) in the scRNA-seq dataset (all P < 2.2×10–16; Wilcoxon test). Epithelial cells are shown in green and stromal cells in pink. E, Schematic overview of the BOSS Biopsy cohort consisting of colon cancer resections from 7 patients each with up to n = 5 multi-regional biopsy samples. Heatmaps of ssGSEA scores for the Hallmark gene sets (F) and TF activity scores for the BOSS Biopsy samples (G). Samples are grouped according to patient of origin and the ESTIMATE Stromal Score of each biopsy sample is indicated by the ESTIMATE StromalScore bar at the top of the heatmap. Only the gene sets/TFs significantly and concordantly enriched in stroma or epithelium in both the LCM discovery and LCM validation cohorts are shown (from Fig. 2; Padj < 0.02 – Hallmarks; P < 0.05 – TFs). Gene sets/TFs with names/symbols colored orange were significantly enriched in stroma in the LCM discovery and LCM validation cohorts and gene sets/transcription factors with names/symbols colored blue were significantly enriched in epithelium in the LCM discovery and LCM validation cohorts. H, Scatterplots showing correlation between the ESTIMATE StromalScore and ssGSEA scores for the Hallmark Epithelial Mesenchymal Transition (left; Spearman rho = 0.96, P = 1.7e-08), KRAS Signaling Up (middle; Spearman rho = 0.87, P = 7.9e-07) and MYC Targets V2 (right; Spearman rho = −0.63, P = 0.00037) gene sets. Samples are colored by patient of origin. CRC, colorectal cancer.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
Single-cell and multi-regional biopsy analyses. A, Schematic of scRNA-seq cohort derived from n = 6 CRC primary tumors. Boxplots showing ssGSEA scores for the Hallmark Epithelial Mesenchymal Transition gene set across the various cell types (B) and specifically between epithelial and stromal cells (C; from all six colorectal cancer tumors) in the scRNA-seq dataset (P < 2.2 × 10–16; Wilcoxon test). D, Comparison of ssGSEA scores for the Hallmark Epithelial Mesenchymal Transition gene set between epithelial and stromal cells in each primary CRC (n = 6) in the scRNA-seq dataset (all P < 2.2×10–16; Wilcoxon test). Epithelial cells are shown in green and stromal cells in pink. E, Schematic overview of the BOSS Biopsy cohort consisting of colon cancer resections from 7 patients each with up to n = 5 multi-regional biopsy samples. Heatmaps of ssGSEA scores for the Hallmark gene sets (F) and TF activity scores for the BOSS Biopsy samples (G). Samples are grouped according to patient of origin and the ESTIMATE Stromal Score of each biopsy sample is indicated by the ESTIMATE StromalScore bar at the top of the heatmap. Only the gene sets/TFs significantly and concordantly enriched in stroma or epithelium in both the LCM discovery and LCM validation cohorts are shown (from Fig. 2; Padj < 0.02 – Hallmarks; P < 0.05 – TFs). Gene sets/TFs with names/symbols colored orange were significantly enriched in stroma in the LCM discovery and LCM validation cohorts and gene sets/transcription factors with names/symbols colored blue were significantly enriched in epithelium in the LCM discovery and LCM validation cohorts. H, Scatterplots showing correlation between the ESTIMATE StromalScore and ssGSEA scores for the Hallmark Epithelial Mesenchymal Transition (left; Spearman rho = 0.96, P = 1.7e-08), KRAS Signaling Up (middle; Spearman rho = 0.87, P = 7.9e-07) and MYC Targets V2 (right; Spearman rho = −0.63, P = 0.00037) gene sets. Samples are colored by patient of origin. CRC, colorectal cancer.